Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide maps of TRIM25 binding sites in triple negative breast cancer cell

ABSTRACT: We report high-throughput profiling of TRIM25 binding sites in triple negative breast cancer cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE79588 | GEO | 2017/04/01

SECONDARY ACCESSION(S): PRJNA316330

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Identification of mRNA bound by TRIM25 binding in triple negative breast cancer

Project description:We report high-throughput profiling of TRIM25 bound mRNA in triple negative breast cancer cells.

2017-04-01 | GSE79587 | GEO

TRIM25

Project description:TRIM25

| PRJNA316328 | ENA

RNA-binding activity of TRIM25 is mediated by its PRY/SPRY domain and is required for ubiquitination

Project description:TRIM25 E3 ubiquitin ligase is a new RNA-binding protein. We present the first high-throughput analysis of the molecular interactomes of TRIM25. We show that TRIM25 is a bona fide RNA-binding protein that interacts with numerous coding and non-coding transcripts. This suggests that TRIM25 could play a role in the regulation of RNA metabolism.

2018-07-27 | GSE104949 | GEO

LINC00461 binding protein in triple negative breast cancer

Project description:Using CHIRP-MS method to detect LINC00461 binding protein in MDA-MB-231 cell line of triple negative breast cancer

2023-04-04 | PXD041363 | iProX

Genome binding pattern of H3K27ac and H3K4me3 in MARCO-TST postive triple-negative breast cancer

Project description:To investigate the transcription start site of MARCO-TST in triple negative breast cancer, we performed endogenous purification of H3K27ac and H3K4me3 under ChIP conditions, followed by high throughput sequencing.

2022-09-28 | GSE214133 | GEO

The Proteomic Landscape of Triple-Negative Breast Cancer

Project description:Triple-negative breast cancer is a heterogeneous disease characterized by poor clinical outcomes and a shortage of targeted treatment options. To discover molecular features of triple-negative breast cancer, we performed quantitative proteomics analysis of twenty human-derived breast cell lines and four primary breast tumors to a depth of more than 12,000 distinct proteins. We used this data to identify breast cancer subtypes at the protein level and demonstrate the precise quantification of biomarkers, signaling proteins, and biological pathways by mass spectrometry. We integrated proteomics data with exome sequence resources to identify genomic aberrations that affect protein expression. We performed a high-throughput drug screen to identify protein markers of drug sensitivity and understand the mechanisms of drug resistance. The genome and proteome provide complementary information that, when combined, yield a powerful engine for therapeutic discovery. This resource is available to the cancer research community to catalyze further analysis and investigation.

2017-12-12 | PXD008222 | Pride

NEK2 regulates triple negative breast cancer transcriptome.

Project description:NEK2 is a mitotic kinase that is upregulated and mislocalized in the nucleus of human cancer cells. NEK2 modulates expression and activity of both transcription and splicing factors in cancer cells, nevertheless whether this kinase affects transcriptome regulation genome widely and whether this activity concurs to its oncogenic activity is still unknown. Herein, by high-throughput RNA sequencing analysis of MDA-MB-231 cells transiently silenced for NEK2 we uncover an extensive modulation of triple-negative breast cancer cell transcriptome by this kinase.

2021-12-21 | GSE140803 | GEO

Effect of depletion of TRIM25 and inhibition of p300 on gene expression in breast cancer cells

Project description:To analyze the effect of TRIM25 on gene expression, TRIM25 was knocked out in MCF7 cells. To understand a possible contribution of p300 on this gene regulation, p300 was inhibited. RNA seq was performed to see changes in the whole transcriptome

2022-10-11 | GSE215084 | GEO

High-throughout sequencing of triple negative breast cancer cells treated actived compound D16

Project description:The high-throughput sequencing technology was performed after the treatment of human triple negative breast cancer cells MDA-MB-231 with the active compound D16 designed and synthesized by ourselves, to explore the expression of genes related to cell proliferation, adhesion, migration and invasion of human triple negative breast cancer cells MDA-MB-231 after the treatment of the active compound Changes to explore the effect of active compounds on the proliferation and motility of triple breast breast cancer cells and to find an interesting target gene, CKAP2.

2021-08-17 | GSE182063 | GEO

Enhancer RNA transcription defines novel CSF1 enhancer in triple-negative breast cancer

Project description:We report the results of employing CRISPR interference (CRISPRi) to epigenetically perturb the CSF1 transcription start site or novel CSF1 enhancer, followed by high-throughput RNA-sequencing to identify downstream gene expression changes in human triple negative breast cancer cells.

2022-04-12 | GSE185318 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data